RP-HPLC method for simultaneous estimation of amlodipine and valsartan in tablet formulation and validation as per ICH guidelines by Bhaisare, Mukesh et al.
342 ISSN 0326-2383
KEY WORDS: Amlodipine besylate, Valsartan, RP-HPLC, Simultaneous estimation.
* Author to whom correspondence should be addressed. E-mail: prof_piyushtrivedi@yahoo.com
Latin American Journal of Pharmacy
(formerly Acta Farmacéutica Bonaerense)
Lat. Am. J. Pharm. 30 (2):  342-6 (2011)
Original Article
Received: June 7, 2010
Revised version: June 30, 2010
Accepted: July 4, 2010
RP-HPLC Method for Simultaneous Estimation of Amlodipine and
Valsartan in Tablet Formulation and Validation as per ICH Guidelines
Mukesh BHAISARE, Kapendra SAHU, C. KARTHIKEYAN,
N.S.H.N. MOORTHY & Piyush TRIVEDI*
School of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidhyalaya,
Airport by pass road, Gandhi nagar, Bhopal-462036, Madhya Pradesh, India
SUMMARY. A simple, specific, sensitive and validated RP-HPLC method for the simultaneous estimation
of amlodipine (AMB) and valsartan (VAL) in marketed tablet formulation was developed. The analysis
was carried out on a phenomenex C18 (250 x 4.6 mm, 5 μm) column using a mobile phase of 0.1% ortho
phosphoric acid solution: acetonitrile (35:65 v/v, pH 3.0). The flow rate of the mobile phase was adjusted
to 1.0 ml/min and was detected at 238 nm. The retention time obtained from the analysis was 1.995 min
and 4.910 min for AMB and VAL respectively. The developed method was validated as per ICH guide-
lines. In order to find out the linearity, the concentrations ranging 2-10 μg/ml for AMB and 64-320 μg/ml
for VAL was used. The squared correlation co-efficient (r 2 value) derived from the equation for AMB and
VAL was 0.9979 and 0.9994, respectively. The percentage recoveries calculated for AMB and VAL ranges
from 96.93 to 99.63 %. The estimated drug in the tablet formulation was 100.13 % and 99.99 % for AMB
and VAL respectively. The results of analysis shows that method can be used for the estimation of AMB
and VAL in the tablet dosage form without further separation in the quality control laboratories. 
